The MHRA has the power to seize unlicensed medicines, shut down websites, and prosecute offenders. They have also issued warnings to the public about the dangers of buying such products online. Companies like Eli Lilly, the manufacturer of genuine tirzepatide (Mounjaro), have been proactive in sending cease-and-desist letters and taking legal action against sellers of counterfeit or unlicensed versions of their drugs.

Synedica UK’s website https://synedica-uk.com provides a textbook case for regulatory action. It is selling a product (Retatrutide) that is not even approved for sale anywhere, let alone in the UK. It is also selling tirzepatide under its research name, directly infringing on pharmaceutical patents and undermining the legal supply chain. The site’s explicit marketing to consumers, combined with its lack of any verifiable regulatory or pharmacy registration, makes it a prime candidate for enforcement.

The crackdown is intensifying, but it is a game of whack-a-mole. As one site is shut down, others appear. The ultimate solution lies in patient education—making it clear that these products are illegal, unregulated, and dangerous—and ensuring that those who need legitimate treatment can access it safely through their doctors.